30 closest matches · ranked by relevance
Cystic Fibrosis · Pancreatic Insufficiency
Primary: Change in Second-phase Insulin Response Derived From the Glucose-potentiated Arginine Test as a Measure of β-cell Sensitivity to Glucose at Baseline and at 6 Months…
Cystic Fibrosis-related Diabetes
Primary: Time in Target — 67; 68 percentage of time in range — p=<0.01
Cystic Fibrosis Related Diabetes · Pancreatic Insufficiency
Primary: BMI — 19.63; 21.19 Kg/m^2
Cystic Fibrosis-related Diabetes
Primary: Percentage of Time in Glucose Target Range (70-180 mg/dl) as Determined by Continuous Glucose Monitor (CGM) on Days 3-14 — 63; 75 percentage of time spent in target…
Cystic Fibrosis
Primary: Percentage Flow-Mediated Dilation (FMD) — 5.64; 5.32; 6.29; 7.21 percentage of change in FMD
Cystic Fibrosis Related Bone Disease
Primary: Bone Microarchitecture and Strength Measures of the Radius and Tibia — 44.6; 40.1; 43.7 mgHA/cm3 — p=0.77
Cystic Fibrosis · Cystic Fibrosis-related Diabetes
Primary: Weight — -4.6 kilograms
Cystic Fibrosis
Primary: Change From Baseline in 2-hour Blood Glucose Levels Following an OGTT to the Average of Week 36 and Week 48 — -35.0 milligrams per deciliter (mg/dl)
Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis
Primary: Coefficient of Fat Absorption (CFA) — 88.1; 89.5 percentage of fat intake
Cystic Fibrosis
Primary: Coefficient of Fat Absorption (%) — 88.62; 49.78 Percentage — p=<0.001
Cystic Fibrosis
Primary: Sputum White Cell Count — 6.93; 6.81 log 10 (cells/mL) — p=0.2772
Cystic Fibrosis
Primary: Kinetic Influx Constant (Ki) — 0.009; 0.013 mL/min/mL
Cystic Fibrosis
Primary: Number of Participants Who Fully Completed at Least One ePRO — 133; 196; 130; 194 Participants
Cystic Fibrosis
Primary: Acute Study: Percentage Flow-Mediated Dilation (FMD) — 7.8; 7.7; 7.3; 6.6 percent flow mediated dilation
Cystic Fibrosis · Pancreatic Exocrine Insufficiency
Primary: Number of Patients With at Least One Treatment Emergent Adverse Event (TEAE) — 9 Participants
Cystic Fibrosis
Primary: Pulmonary Function Testing — 1.9; 2.0 L/sec
Cystic Fibrosis
Primary: Change in FEV1 Percentage Predicted From Baseline — 11.8; 8.8 percentage of predicted
Cystic Fibrosis · Lung Transplant
Primary: Steady-state Pharmacokinetics of Mycophenolic Acid and Mycophenolic Acid Glucuronide in Stable Cystic Fibrosis and Non-Cystic Fibrosis Lung Transplant Recipients…
Cystic Fibrosis · Pancreatic Exocrine Insufficiency
Primary: Coefficient of Fat Absorption (%) — 47.41; 82.81 Percentage — p=<0.001
Exocrine Pancreatic Insufficiency in Subjects With Cystic Fibrosis
Primary: Coefficient of Fat Absorption (CFA) — 71.0; 70.9; 71.8; 75.9 percentage of fat intake
Cystic Fibrosis
Primary: Change in FEV1 — -0.07; -0.08 Liters
Type 1 Diabetes
Primary: Improvement in Glucose Regulation — 34.42; 34.42; 35.44; 39.03 ng*hr/mL — p=0.43
Cystic Fibrosis
Primary: Sweat Chloride Concentration — NA mmol/L
Cystic Fibrosis · Liver Fibrosis
Primary: Elastographic Value in kPa Measured by Fibroscan — 4.7 kPa
Cystic Fibrosis · Exocrine Pancreatic Insufficiency · Pancreatic Diseases
Primary: Number of Patients With Adverse Drug Reaction — 1 participants
Cystic Fibrosis
Primary: Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE) — 46; 32; 32; 2 Participants
Cystic Fibrosis · Chronic Pancreatitis
Primary: Mean Change in Total Symptom Score (TSS) From Day 1 (Baseline) to Days 8, 15, 29, and 85 — 0.0012; 0.0480; 0.1506; 0.0791 score on a scale
Cystic Fibrosis
Primary: Metabolic Clearance of D6-25(OH)D3 — 397; 342 mL/day
Exocrine Pancreatic Insufficiency (EPI) · Cystic Fibrosis (CF)
Primary: Efficacy of MS1819-SD: Coefficient of Fat Absorption (CFA) — 55.6; 86.2 % CFA
Cystic Fibrosis
Primary: Percentage of Predicted Function (Percent-Predicted) of Forced Expiratory Volume in One Second (FEV1) at Baseline — 62.092; 60.232 percentage of predicted FEV1 — p=0.3264